This important study demonstrates the potential of synthetic gene circuits to detect and target aberrant RAS activity in cancer cell lines. The circuit design is novel and the evidence supporting the ...

Sorafenib is an oral tyrosine kinase inhibitor able to inhibit VEGF receptors 1, 2 and 3, PDGF receptors α and β, RET, Flt3, c-KIT and the RAF kinase and MAPK pathways. Over 10,000 patients have ...

A recent study led by Associate Professor Takuya Yamamoto and Researcher May Nakajima-Koyama has revealed that maintaining a ...

A recent study led by Associate Professor Takuya Yamamoto and Researcher May Nakajima-Koyama has revealed that maintaining a delicate balance between interferon-gamma (IFN-γ) and extracellular ...

Pasithea Therapeutics Corp. (KTTA) stock has reached a new 52-week low, trading at $1.32 USD, as investors navigate a tumultuous market environment. With a market capitalization of just $1.79 million ...

GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN –– Approval based on positive data ...

Cell cycle re-entry of senescent breast cancer cells after CDK4/6 inhibition (CDK4/6i) constitutes a major source of disease ...

Immune checkpoint inhibitors (ICIs) have transformed cancer therapy by targeting key immune pathways such as PD-1, PD-L1, CTLA-4, and LAG-3 to enhance the immune system's ability to combat ...

Given the success of the previous Research Topic 'Exploring Small Molecule Inhibitors in Cardiovascular and Cerebrovascular Diseases', we are pleased to ...

The secretion of IL-6 was monitored by ELISA in cell culture supernatants from conventional cultured FLS treated with NaHS or MAPK inhibitors. In addition, FLS were grown in 3-dimensional ...

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced significant findings about ATI-2138, a novel investigational drug ...

CIRBP Family, Tumors, Molecular Mechanisms, RNA-Binding Proteins, Cellular Stress Share and Cite: Cai, Y. , Wang, T. and Zhan ...